Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
RMC-GI-102
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT06445062 ↗
- Recruiting
- Revolution Medicines, Inc.
- Deep
We haven't built an HCP commentary report on RMC-GI-102 (RMC-6236, mFOLFOX6 regimen and 7 more in Colorectal Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RMC-GI-102 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 17 | |
| YouTube | 4 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- RMC-6236; mFOLFOX6 regimen; bevacizumab; mFOLFIRINOX regimen; cetuximab; gemcitabine; nab-paclitaxel; RMC-9805; FOLFIRI regimen
- Arms
- Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol C: metastatic PDAC · Experimental
- Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC · Experimental
- Subprotocol F: RAS G12D-mutated metastatic PDAC · Experimental
- Subprotocol G: RAS G12D-mutated metastatic CRC · Experimental
- Enrollment
- 1,130 (estimated)
- Primary outcomes
- Adverse events (Subprotocols A-F)
- Dose limiting toxicities (Subprotocols A-F)
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by Blinded Independent Central Review (BICR)(Subprotocol G)
- Sponsor
- Revolution Medicines, Inc.
- Start
- May 24, 2024
- Primary completion
- Sep 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06445062 · updated Sep 22, 2026
Publications
linked from the registry- Cregg J, Edwards AV, Chang S, Lee BJ, Knox JE, Tomlinson ACA, Marquez A, Liu Y, Freilich R, Aay N, Wang Y, Jiang L, Jiang J, Wang Z, Flagella M, Wildes D, Smith JAM, Singh M, Wang Z, Gill AL, Koltun ES. Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J Med Chem. 2025 Mar 27;68(6):6064-6083. doi: 10.1021/acs.jmedchem.4c02314. Epub 2025 Mar 8. PubMed 40056080